Drug discovery technologies

Ruffolo R. Re-engineering discovery and development impact on the pharmaceutical industry of tomorrow. In Drug Discovery Technology Europe 2005, IBC Life Sciences. 

Schuster, D., Laggner, C., Steindl, T.M. and Langer, T. (2006) Development and validation of an in silico P450 profiler based on pharmacophore models. Current Drug Discovery Technologies, 3, 1—48. 

One hundred years of drug discovery technologies. (Redrawn from Adkins, S. et al., New Drug Discovery Is Genomics Delivering Lehman Brothers Research Reports, 1999.)... 

The advances of drug discovery technologies have been spectacular in the last two decades yet they failed to improve the discovery of more disease-ameliorating molecules. The productivity of new drugs did not match the concomitant increased investment and technological efforts. 

Kumar, S. and Gunnarsson, K. Small molecule drug screening based on surface plasmon resonance. In Advantages of Drug Discovery Technology, Harvey, A.L (Ed.). Wiley, Chichester, UK, 1998, 97-114. 

LaBrie, S., Protein analysis in an array format using a novel, highly sensitive detection system. Presentation, International Business Communication, Drug Discovery Technologies, Session FI, Boston, MA, 2001. 

From a historical point of view, the research axes of the pharmaceutical industry have shifted away from acute and more toward chronic pathology solutions. The drug discovery technologies have evolved in parallel because the cost of the research linked to the failure rate has increased with the complexity of the pathology of interest. As a consequence, in order to enhance research... 

P.A. Keifer, The NMR toolkit for compound characterization, Integrated Drug Discovery Technologies, 485 541, 2002. 

The discovery and development of a new medicine is long, complex, and requires extensive resources, including the use of experimental animals and humans in clinical trials. Despite technical progress in drug discovery technologies, there is no concomitant increase in understanding the clinical basis of disease and therefore the development of novel effective therapies. Today the rate of failure of new medicines poses a difficult challenge to the industry. 

Ley S.V., Baxendale, I.R. and Myers, R.M. (2006) Polymer-supported reagents and scavengers in synthesis, in Comprehensive Medicinal Chemistry II, Drug Discovery Technologies, vol. 3 (eds D.J. Triggle and J. B. Taylor), Elsevier, Oxford, pp. 791-836. 

L. J. Gershell and J. H. Atkins, A brief history of novel drug discovery technologies, Nature Rev. Drug Discovery 2 (2003), 321-327. 

CONTRERA J. F., MACLAUGHLIN p., HALL L. H. and KIER, L. B. (2005), QSAR modeling of carcinogenic risk using discriminant analysis and topological molecular descriptors . Current Drug Discovery Technologies, 2, 55-67. 

Mei, Houng-Yau, Anthony W. Czarnik, and ebrary Inc. Integrated Drug Discovery Technologies. New York Marcel Dekker, 2002. 

Balakin, K.V., Ivanenkov, Y.A., Savchuk, N.P., Ivashchenko, A.A. and Ekins, S. (2005) Comprehensive computational assessment of ADME properties using mapping techniques. Current Drug Discovery Technologies, 2 (2),... 

Profile AXYS is involved in the integration of drug discovery technologies from gene identification through clinical development and is focused on the discovery of small-molecule therapeutics. 

---